M. Scott Lucia, MD

M. Scott Lucia, MD

University of Colorado, Denver

Aurora, Colorado

M. Scott Lucia, MD is Professor and Vice Chair of Anatomic Pathology and Chief of Genitourinary and Renal Pathology at the University of Colorado Anschutz Medical Campus (UCAMC) School of Medicine, where he also serves as the Director of the Prostate Cancer Research Laboratories and UCAMC Biorepository Core Facility. Dr. Lucia received his MD from the University of Colorado School of Medicine in 1988. He completed his internship and residency in pathology at the University
of Colorado in 1993. He was a research fellow in the Laboratory of Chemoprevention at the National Institutes of Health from 1993 to 1995 before returning to the University of Colorado in 1995. Dr. Lucia served as the primary pathologist for the Prostate Cancer Prevention Trial (PCPT) and Vitamin
E and Selenium Chemoprevention Trial (SELECT), sponsored by the Southwest Oncology Group, the
Medical Therapy of Prostate Symptoms (MTOPS) trial, sponsored by the NIDDK, and the Reduction with Dutasteride of Clinical Progression Events in Expectant Management of Prostate Cancer (REDEEM) sponsored 
by GlaxoSmithKline. He directs the operation of several tissue and serum biorepositories for prostate and prostatic diseases including those for the PCPT, MTOPS, SELECT, and the University of Colorado Cancer Center Prostate Biorepository. He has authored or co-authored over 25 peer-reviewed articles, reviews, editorials and book chapters. His primary areas of interest include pathology of prostate cancer and hyperplasia, early detection and prevention of prostate cancer, prostate cancer biomarkers, and mechanisms of carcinogenesis.

Articles by M. Scott Lucia, MD

Changing Distribution, Size and Grade of Prostate Cancer: Whole-Mount Prostatectomy Analysis

M. Scott Lucia, MD, summarizes the changes in the clinical management of prostate cancer since 1990, specifically regarding PSA screening, active surveillance, targeted focal therapy, and pathology grading practices. Also, he analyzes whole-mount prostatectomy data from the past 16 years that has shown increasingly higher grade and volume tumors. He then discusses whether or not this is exclusively due to patient selection and over-grading.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -